跳转至内容
Merck
CN

420119

SP600125

≥98% (HPLC), solid, JNK inhibitor, Calbiochem®

别名:

JNK抑制剂II

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C14H8N2O
化学文摘社编号:
分子量:
220.23
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

JNK抑制剂II, JNK Inhibitor II. SP600125, CAS 129-56-6, is a potent, cell-permeable, selective, and ATP competitive inhibitor of c-Jun N-terminal kinase (JNK; IC50 = 40 nM for JNK-1 & JNK-2 & 90 nM for JNK-3).

Quality Level

description

RTECS - CB4585000

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

yellow-orange

solubility

DMSO: 15 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[nH]1nc2c3c1[c]4[c]([c]([c]3=CC=C2)=O)=CC=CC=4

InChI

1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)

InChI key

ACPOUJIDANTYHO-UHFFFAOYSA-N

General description

一种有效的,细胞可渗透的,选择性并可逆的c-Jun N末端激酶(JNK)抑制剂(JNK-1和JNK-2的IC50 = 40 nM,JNK-3的IC50=90 nM)。这种抑制对于ATP具有竞争性。与ERK1和p38-2 MAP激酶相比,对JNK的选择性高300倍以上。抑制c-Jun的磷酸化,阻断IL-2、IFN-γ、TNF-α、COX-2的细胞表达。阻断IL-1诱导的磷酸化-Jun积累和c-Jun转录的诱导。也可使用50 mM(5 mg/454 µl)JNK抑制剂II(目录号420128)的DMSO溶液。

Biochem/physiol Actions

主要靶标
JNK 1,JNK 2,JNK 3
产物与ATP竞争。
可逆性:是
细胞可渗透性:是
靶标IC50:40 nM,对于JNK-1和JNK-2;90 nM,对于JNK-3

Packaging

用惰性气体包装

Preparation Note

复溶后,等分并在-20°C下冷冻保存。储备溶液在-20°C下可稳定保存2个月。
对于每10 µM浓度的JNK抑制剂II,在培养基中应包含0.1%DMSO。培养基的预热和向培养基中添加BSA可能会增强其溶解度。

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

毒性:标准处理(A)


Still not finding the right product?

Explore all of our products under JNK抑制剂II


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

Human Kinome Poster: The InhibitorSelect™ Protein Kinase Inhibitor Libraries provide broad coverage of the human kinome as shown here. The depicted human kinome dendrogram of 518 kinases are classified into five broad groups, 90 families, and 145 subfamilies. Inhibitor coverage was assigned based upon published data related to potency (IC50, EC50, Kd, etc.) for individual kinases harvested from the literature. Colored dots denote which library contains an inhibitor with demonstrated potent activity against the designated kinase and do not necessarily reflect known specificity of the inhibitor. Coverage of lipid and atypical kinases are depicted as a separate dendrogram. As shown, Calbiochem® Protein Kinase Inhibitor Libraries cover all major kinase families including TK, CMGC, CAMK, AGC, CK1, STE, TKL, as well as Lipid or Atypical kinase families.


Dai-Xu Li et al.
General physiology and biophysics, 39(6), 545-555 (2020-11-24)
Cardiovascular disease (CVD) states are associated with endothelial dysfunction (ED) and increased production of ROS in endothelial cells. The present study aimed to explore the protective effects of antioxidant protein peroxiredoxin 6 (PRDX6) on angiotensin II (AngII)‑induced human umbilical vein
Jia He et al.
Frontiers in immunology, 12, 760138-760138 (2022-01-25)
Idiopathic pulmonary fibrosis (IPF) is a group of chronic interstitial pulmonary diseases characterized by an inexorable decline in lung function with limited treatment options. The abnormal expression of transforming growth factor-β (TGF-β) in profibrotic macrophages is linked to severe pulmonary
Fiorella Carla Grandi et al.
Science advances, 6(11), eaay5352-eaay5352 (2020-03-24)
Aging or injury leads to degradation of the cartilage matrix and the development of osteoarthritis (OA). Because of a paucity of single-cell studies of OA cartilage, little is known about the interpatient variability in its cellular composition and, more importantly



全球贸易项目编号

货号GTIN
420119-5MG07790788050092
420119-25MG04055977187977
420119-50MG04055977187991